Participant flow

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer · Source last updated 2023-08-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive oral exemestane (25 mg) once daily for 5 years. exemestane: Given orally

   id

   FG000

   title

   Exemestane

2. description

   Patients receive oral anastrozole (1 mg) once daily for 5 years. anastrozole: Given orally

   id

   FG001

   title

   Anastrozole

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         28

      2. group Id

         FG001

         num Subjects

         28

      type

      Did not received protocol treatment

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         3789

      2. group Id

         FG001

         num Subjects

         3787

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3761

      2. group Id

         FG001

         num Subjects

         3759

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         28

      2. group Id

         FG001

         num Subjects

         28

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice